Abstract 3373
Background
The role of surgical resection remains controversial in small cell lung cancer (SCLC) although there are some retrospective and population-based studies indicate that patients with very early stage SCLC has longer survival compared with those not given surgery. The specific aim of this study was to identify the survival benefit of surgery for patients with Stage IA-IIB SCLC and nomogram predictive model was created to select patients who are eligible to surgery.
Methods
Patients diagnosed with stage IA-IIB SCLC between 2004 and 2014 were selected from the SEER database. The primary endpoint was overall survival. Multivariate Cox proportional regression and coefficients of the predictors were calculated. A nomogram was constructed for predicting 1- and 3-year overall survival probability. All statistical analysis was performed with R software.
Results
2246 patients with stage I-II were enrolled. 618 (27.5%) received surgery and 1628 (72.5) not. Unadjusted median overall survival (OS) was 23 months (95% CI: 21-24), which was 35 months (95% CI: 31-44) vs. 19 months (95% CI: 18-21) in surgery and non-surgery groups respectively (p <0.0001). We used a propensity score to balance observed covariates. OS benefit was observed in all subgroups between the surgery and non-surgery group except in the non-White race, well or moderately grading, stage IIA or IIB and N1 lymph involvement. Multivariate Cox proportional hazards regression analysis showed a survival benefit in the surgery group compared with non-surgery group no matter balanced by propensity score weighting or not. The competing-risks nomogram was built for predicting 1-year and 3-year survival. The age, tumor size, extent of tumor, N0/1 and surgery with radiation and chemotherapy were introduced as variables. The calibration of internal validation for predicting survival at 1 and 3-year by this nomogram-predicted probability was identical to the actual probability.
Conclusions
Surgery was proved to benefit patients with stage IA-IIB SCLC by this relatively large number population-based study and a nomogram built from a parametric survival model from the SEER database can be used to predict which patients with stage IA-IIB SCLC may benefit from surgery.
Clinical trial identification
Legal entity responsible for the study
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department 1 of Thoracic Oncology Medicine, Peking University Cancer Hospital & Institute.
Funding
National Natural Science Foundation of China, Award ( 81401914) and Beijing Municipal Administration of Hospitals' Youth Programme (20161112).
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract